# Karin Fijnvandraat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7614399/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 64 papers | 1,740 citations | 318942 23 h-index | 325983 40 g-index |
| 64 all docs | 64 docs citations | 64 times ranked | 1876 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thrombosis and Haemostasis, 2022, 122, 208-215. | 1.8 | 7 |
| 2 | Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease. British Journal of Haematology, 2022, 196, 769-776. | 1.2 | 6 |
| 3 | Joint status of patients with nonsevere hemophilia A. Journal of Thrombosis and Haemostasis, 2022, 20, 1126-1137. | 1.9 | 17 |
| 4 | Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. Haemophilia, 2022, 28, 278-285. | 1.0 | 1 |
| 5 | Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Advances, 2022, 6, 5317-5326. | 2.5 | 2 |
| 6 | The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265. | 2.5 | 10 |
| 7 | SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011. | 1.9 | 6 |
| 8 | Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. British Journal of Clinical Pharmacology, 2021, 87, 2602-2613. | 1.1 | 6 |
| 9 | Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. HemaSphere, 2021, 5, e542. | 1.2 | 5 |
| 10 | Population pharmacokinetics of the von Willebrand factorâ€“factor VIII interaction in patients with von Willebrand disease. Blood Advances, 2021, 5, 1513-1522. | 2.5 | 5 |
| 11 | Adoption of emicizumab (HemlibraÂ®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia, 2021, 27, 736-743. | 1.0 | 11 |
| 12 | Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. Lancet Haematology,the, 2021, 8, e492-e502. | 2.2 | 9 |
| 13 | Treatmentâ€related risk factors for inhibitor development in nonâ€severe hemophilia A after 50 cumulative exposure days: A caseâ€control study. Journal of Thrombosis and Haemostasis, 2021, 19, 2171-2181. | 1.9 | 8 |
| 14 | Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood, 2021, 138, 2853-2873. | 0.6 | 23 |
| 15 | Prophylaxis in children with haemophilia in an evolving treatment landscape. Haemophilia, 2021, 27, 889-896. | 1.0 | 9 |
| 16 | The factor VIII treatment history of nonâ€severe hemophilia Aâ€”Response from original authors Abdi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 2642-2644. | 1.9 | 1 |
| 17 | One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate PÂ®/Humate PÂ® treatment in von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2020, 18, 295-305. | 1.9 | 6 |
| 18 | The factor VIII treatment history of nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 3203-3210. | 1.9 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Review of Hematology, 2020, 13, 313-321. | 1.0 | 15 |
| 20 | Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a caseâ€'control study. British Journal of Haematology, 2020, 189, 1182-1191. | 1.2 | 3 |
| 21 | Hemophilia management: Huge impact of a tiny difference. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 377-385. | 1.0 | 6 |
| 22 | Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. Blood, 2020, 136, 15-16. | 0.6 | 0 |
| 23 | Identification of genetic biomarkers for alloimmunization in sickle cell disease. British Journal of Haematology, 2019, 186, 887-899. | 1.2 | 14 |
| 24 | Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease. Frontiers in Immunology, 2019, 10, 185. | 2.2 | 43 |
| 25 | BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. American Journal of Hematology, 2019, 94, E201-E205. | 2.0 | 15 |
| 26 | Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates. Haematologica, 2019, 104, 2300-2306. | 1.7 | 16 |
| 27 | Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood, 2019, 134, 2354-2360. | 0.6 | 41 |
| 28 | Sports participation and physical activity in patients with von Willebrand disease. Haemophilia, 2019, 25, 101-108. | 1.0 | 14 |
| 29 | Randomized Trial of Platelet-Transfusion Thresholds in Neonates. New England Journal of Medicine, 2019, 380, 242-251. | 13.9 | 288 |
| 30 | The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease. Blood, 2019, 134, 2275-2275. | 0.6 | 0 |
| 31 | Intracranial 4D flow magnetic resonance imaging reveals altered haemodynamics in sickle cell disease. British Journal of Haematology, 2018, 180, 432-442. | 1.2 | 14 |
| 32 | Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study. Thrombosis and Haemostasis, 2018, 118, 152-160. | 1.8 | 15 |
| 33 | Effect of Nâ€acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial. British Journal of Haematology, 2018, 182, 444-448. | 1.2 | 27 |
| 34 | Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. Thrombosis and Haemostasis, 2018, 118, 1690-1700. | 1.8 | 10 |
| 35 | Comorbidities associated with higher von Willebrand factor (<scp>VWF</scp>) levels may explain the ageâ€related increase of <scp>VWF</scp> in von Willebrand disease. British Journal of Haematology, 2018, 182, 93-105. | 1.2 | 39 |
| 36 | Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?. Seminars in Thrombosis and Hemostasis, 2018, 44, 531-543. | 1.5 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. Journal of Clinical and Translational Research, 2018, , . | 0.3 | 1 |
| 38 | Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. Journal of Clinical and Translational Research, 2018, 3, 351-357. | 0.3 | 1 |
| 39 | Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica, 2017, 102, 1486-1493. | 1.7 | 24 |
| 40 | Differences between Platelets Derived from Neonatal Cord Blood and Adult Peripheral Blood Assessed by Mass Spectrometry. Journal of Proteome Research, 2017, 16, 3567-3575. | 1.8 | 28 |
| 41 | To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity. Blood Reviews, 2017, 31, 339-347. | 2.8 | 30 |
| 42 | Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307. | 1.2 | 56 |
| 43 | Daily pain in adults with sickle cell diseaseâ€”a different perspective. American Journal of Hematology, 2017, 92, 179-186. | 2.0 | 11 |
| 44 | Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. Blood Advances, 2017, 1, 1598-1616. | 2.5 | 34 |
| 45 | The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors. Thrombosis and Haemostasis, 2016, 115, 543-550. | 1.8 | 26 |
| 46 | Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease. British Journal of Haematology, 2016, 172, 274-284. | 1.2 | 25 |
| 47 | A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica, 2016, 101, 1159-1169. | 1.7 | 39 |
| 48 | Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. American Journal of Hematology, 2016, 91, 763-769. | 2.0 | 48 |
| 49 | In Vivo T1 of Blood Measurements in Children with Sickle Cell Disease Improve Cerebral Blood Flow Quantification from Arterial Spin-Labeling MRI. American Journal of Neuroradiology, 2016, 37, 1727-1732. | 1.2 | 37 |
| 50 | von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood, 2015, 125, 3006-3013. | 0.6 | 62 |
| 51 | Bleeding spectrum in children with moderate or severe von <scp>W</scp>illebrand disease: <scp>R</scp>elevance of pediatricâ€specific bleeding. American Journal of Hematology, 2015, 90, 1142-1148. | 2.0 | 46 |
| 52 | Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thrombosis and Haemostasis, 2015, 114, 46-55. | 1.8 | 33 |
| 53 | The â€œOPTI-CLOTâ€•trial. Thrombosis and Haemostasis, 2015, 114, 639-644. | 1.8 | 22 |
| 54 | Volume of White Matter Hyperintensities Predicts Neurocognitive Functioning in Children with Sickle Cell Disease. Blood, 2014, 124, 2720-2720. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: â€œTackling a Moving Targetâ€•(â€œOPTI-CLOTâ€•Studies). Blood, 2014, 124, 5031-5031. | 0.6 | 0 |
| 56 | Towards Successful Implementation of Pharmacokinetic-Guided Prophylactic Dosing of Clotting Factor Concentrate in Hemophilia; The Doâ€™s and Donâ€™ts after Discrete Choice Experiment Analysis. Blood, 2014, 124, 5038-5038. | 0.6 | 0 |
| 57 | Cognitive functioning in young adult patients with sickle cell disease. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 14-14. | 0.0 | 0 |
| 58 | Cerebral imaging with 7-Tesla MRI in patients with sickle cell disease: a pilot study. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 76-76. | 0.0 | 0 |
| 59 | Diagnosis and management of haemophilia. BMJ, The, 2012, 344, e2707-e2707. | 3.0 | 82 |
| 60 | Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thrombosis and Haemostasis, 2012, 108, 683-692. | 1.8 | 87 |
| 61 | Immunobiology of Inhibitor Development in Hemophilia A. Seminars in Thrombosis and Hemostasis, 2003, 29, 061-068. | 1.5 | 15 |
| 62 | A Human Alloantibody Interferes With Binding of Factor IXa to the Factor VIII Light Chain. Blood, 1998, 91, 2347-2352. | 0.6 | 57 |
| 63 | Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. British Journal of Haematology, 1995, 91, 474-476. | 1.2 | 96 |
| 64 | Coagulation Activation and Tissue Necrosis in Meningococcal Septic Shock: Severely Reduced Protein C Levels Predict a High Mortality. Thrombosis and Haemostasis, 1995, 73, 015-020. | 1.8 | 162 |